Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-rich plasma (University of the Basque Country)
- Development stage
- Unknown
- Lead developer
- University of the Basque Country
- Administration
- Intramuscular
01
Overview
Platelet-rich plasma (PRP) is an autologous biological therapy being investigated by the University of the Basque Country (UPV/EHU) for the treatment of acute muscle injuries, specifically in professional football players. The therapy involves concentrating a patient's own platelets, which, upon activation, release a variety of growth factors and bioactive molecules (such as PDGF, TGF-β, and VEGF) that facilitate muscle tissue regeneration and repair. In the clinical trial NCT03676205, the PRP is prepared using the Ortho pras® system and administered via ultrasound-guided intramuscular injections. The study aims to evaluate whether PRP reduces the time to return to play and decreases injury recurrence compared to homeopathic treatments.
- Brand names
- Ortho pras
- Other names
- PRPautologous platelet-rich plasma
02
Targets
FGFR (Fibroblast growth factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR1/TGFBR2 (Transforming growth factor-beta receptor type 1 / Transforming growth factor-beta receptor type 2)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR (FGFR family)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on platelet-rich plasma (University of the Basque Country).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-rich plasma (University of the Basque Country).